OBJECTIVE-To determine the relationship between mean sensor glucose concentrations and hemoglobin A 1c (HbA 1c ) values measured in the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications laboratory at the University of Minnesota in a cohort of subjects with type 1 diabetes from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial.
H emoglobin A 1c (HbA 1c ) is a timehonored gold standard measure of overall diabetes control, and HbA 1c values serve as the targets for diabetes management (1) . The chemistry of glycation predicts a straightforward relationship between mean glucose concentrations and HbA 1c values over the average lifespan of a patient's red cells (2) . Because the Diabetes Control and Complications Trial (DCCT) (3) demonstrated that improved glycemic control, measured as HbA 1c , decreased the risk of long-term diabetic complications, most HbA 1c measurements have been standardized to the DCCT values via the National Glycohemoglobin Standardization Program. Current HbA 1c assays can be fast, precise, and accurate (4) .
Determining the true relationship between mean glucose concentrations and HbA 1c values has been hampered by limitations in accessing mean glucose concentrations in groups of patients over a period of $3 months. Discrete glucose measurements obtained infrequently over the day often fail to capture the true magnitude of glycemic excursions commonly found in patients with type 1 diabetes (5) and underestimate the extent and frequency of nocturnal hypoglycemia (6) .
In contrast, the recently completed Juvenile Diabetes Research Foundation (JDRF)-sponsored continuous glucose monitoring (CGM) trial provided data to closely examine the relationship between mean glucose concentrations, measured in a near-continuous fashion for 3 months, and the subsequent HbA 1c values measured centrally in the DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) laboratory in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS-The JDRF CGM randomized trial protocol has been described in detail previously (7) (8) (9) . Major eligibility criteria included age .8 years, type 1 diabetes for at least 1 year, use of either an insulin pump or at least three daily insulin injections, and an HbA 1c value ,10.0%. Subjects were randomly assigned to either a CGM group or a control group that used standard home blood glucose monitoring for the first 6 months. After 6 months, both groups used CGM.
Subjects received one of the following CGM devices: the DexCom SEVEN (DexCom, San Diego, CA), the MiniMed Paradigm REAL-Time insulin pump and continuous glucose monitoring system (Medtronic MiniMed, Northridge, CA), or the FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA). Each subject was instructed to wear the sensor on a continuous basis.
HbA 1c values were measured at the University of Minnesota using the Tosoh HbA 1c 2.2 Plus Glycohemoglobin Analyzer (10) . The cohort did not contain enough non-white or Hispanic subjects to evaluate race/ethnicity.
Statistical analysis
We limited our analysis to subjects who averaged $4 days per week of CGM use in the 3 months before an HbA 1c measurement. To minimize the impact of changing glycemic control after the introduction of CGM, we only analyzed the 3 months of CGM data collected before the 12-month (end-of-study) HbA 1c measurement. An HbA 1c value was obtained for 436 subjects who completed the 12month visit. Of these, 252 subjects had worn their CGM device for an average of $4 days per week during the prior 3 months and were included in these analyses.
Mean glucose concentrations were calculated over the 91-day period before the HbA 1c measurement, giving equal weight to each of the 24 h of the day. Similar calculations were done for the mean glucose values during the 1-month (30-day) and 2-month (61-day) intervals before the HbA 1c measurement. Leastsquares regression analysis was performed using mean glucose concentration as the dependent variable and HbA 1c as the independent variable (linear term). Fitting higher order polynomial terms showed no deviation from linearity. Residual values were examined to verify that they followed an approximate normal distribution. No outliers or overly influential data points were identified. A plot of residuals against predicted values showed no meaningful deviation from the assumption of homoscedasticity.
RESULTS-At the 12-month visit, the 252 subjects in analysis ranged in age from 9 to 74 years (mean 6 SD: 32 6 17), with 21% of subjects ,15 years, 24% between 15 and 24 years, and 55% $25 years. Median duration of diabetes was 7 years (25th to 75th percentile, 4-9) for children, 8 years (5-10) for adolescents, and 24 years (17-32) for adults; 54% were female and 94% were white. HbA 1c values ranged from 5.1 to 9.6% (7.1 6 0.8%). Approximately half of subjects had a stable HbA 1c value, with 55% being within 60.2% of the HbA 1c value measured 3 months prior, 21% improving $0.3%, and 24% worsening $0.3% over the last 3 months. In total, 346,434 h of CGM glucose values (median 1,433 h per subject) were analyzed.
The slope (95% CI) for mean sensor glucose concentration (area under the curve) versus a centrally measured HbA 1c was 24.4 mg/dL (22.0-26.7) for each 1% change in HbA 1c with an intercept of 216.2 mg/dL (232.9 to 0.6) ( Fig. 1 and Table 1 ). Using only 1 or 2 months of glucose data before the HbA 1c measurement did not alter the slope (Table 1) .
The slope of mean glucose concentration versus HbA 1c value did not vary meaningfully by age, sex, or type of CGM device (Table 1) . Although only 42 of the 252 subjects were not insulin pump users, the mode of insulin delivery did not materially alter the slope. Reanalyzing the data using only the 195 subjects whose HbA 1c remained within 60.4% of the value obtained 3 months earlier or the 138 subjects whose HbA 1c remained within 60.2% did not materially alter the slopes.
Substantial individual variability existed in the relationship between HbA 1c and mean glucose concentration. For HbA 1c values between 6.9 and 7.1% (n = 46), the average sensor mean glucose concentrations ranged from 128 to 187 mg/dL. For HbA 1c values between 7.9 and 8.1% (n = 16), the average sensor mean glucose concentrations ranged from 154 to 223 mg/dL (Fig. 1 ). The root mean square of the errors between the actual mean sensor glucose concentration versus the value calculated using the regression equation was 14.3 mg/dL, whereas the median absolute difference was 10.1 mg/dL. A total of 91% of subjects had mean glucose concentrations within 615% of the calculated average glucose concentrations (calculated from HbA 1c ).
CONCLUSIONS-
The estimated slope of the relationship between mean glucose concentration and HbA 1c has varied from study to study (Table 2 ). In studies that used infrequent discrete blood glucose testing, Hempe et al. (11) found a slope of 18.5 mg/dL for each unit (%) change in HbA 1c , whereas Rohlfing et al. (12) and Makris et al. (13) found slopes of ;35 mg/dL for each unit (%) change in HbA 1c , a number that was used to describe the relationship for a decade. These investigators also found wide variability between measured mean glucose concentrations and estimated average glucose values calculated using their regression equations. In our study, the slope of the regression line was 24-25 mg/dL glucose for every 1% change in HbA 1c . This value is lower than values reported earlier using six to seven intermittent sample blood glucose profiles (11, 12) but similar to the results of other studies that used CGM (14) (15) (16) . For example, using CGM, Mazze (14) found a slope of 26.3 with mean glucose concentration as the dependent variable.
Nathan et al. (15) and Borg et al. (17) used a combination of both intermittent discrete and intermittent CGM data from adults with and without diabetes. They found a slope of 28.7 mg/dL glucose for every 1% change in HbA 1c using CGM data (15) , which was also similar to the value in the current study, and a correlation of 0.89 between HbA 1c and mean glucose using CGM and self-monitoring blood glucose data combined (17) .
It is not surprising that the relationship between measured glucose concentrations and HbA 1c differs with the use of CGM compared with episodic blood glucose monitoring. One might expect that the addition of a more complete 24-h measure of glucose concentrations would provide a tighter and more accurate assessment of the relationship between glucose concentrations and HbA 1c values. There are limitations to the determination of the relationship between glucose and HbA 1c with the current study. However, we did not find any major differences in the relationships between glucose concentrations and HbA 1c values when considering patients whose HbA 1c was stable and patients whose HbA 1c changed over the time interval of observation. Individual biological variation in erythrocyte survival or glycation rates might contribute to the discrepancy between estimated and measured mean glucose concentrations in individual subjects. Future analysis will examine the consistency of the relationship between glucose and HbA 1c in the same patient over time.
Subgroup analyses in our study showed that the slope of mean glucose concentration versus HbA 1c value was not clinically or statistically different by agegroup, sex, or sensor type. In our study, we did not have a sufficient number of non-white subjects to evaluate the relationships of mean glucose concentration versus HbA 1c in other ethnic and racial groups.
It is important to note that all studies have reported substantial variability between the measured mean glucose concentrations and the estimated values calculated from regression equations ( Table 2) . As an example, Nathan et al. (15) reported that only slightly ,90% of subjects had measured glucose concentrations within 615% mean glucose concentrations predicted by HbA 1c . We found a similar value in the current study (91%).
CGM typically has a relative error ranging from 14 to 20% (18) (19) (20) (21) . Quality control samples conducted during this study for HbA 1c , in contrast, showed that 99% of repeat measurements were within 60.1% of the original value. This result suggests that the measurement error for HbA 1c is negligible compared with that for CGM used to calculate the mean glucose in this analysis.
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